Related medicinesInsulin humanInsulin lisproInsulin aspartInsulin glargineInsulin degludecInsulin icodec
Where it comes from
- Made in
- Beta cells of the pancreatic islets
- Sent out by
- Rising blood glucose after a meal, helped along by the gut incretins GLP-1 and GIP and by amino acids
- Acts on
- Liver
- Skeletal muscle
- Fat tissue
- Brain
What it does
In medicine
- Insulin therapy since 1922: human insulin and analogues such as lispro, aspart, glargine and degludec
- Type 1 diabetes is its absence; type 2 begins as resistance to it 1
- C-peptide, cut from the same precursor, is measured to tell how much insulin a pancreas still makes
Beyond the body’s own use
- Pumps joined to a glucose sensor, the “closed loop” or artificial pancreas, now adjust the dose themselves and raise the time spent in range in randomised trials; inhaled insulin is approved and little used
- A once-weekly insulin, icodec, is approved in Europe (2024) and the United States (2026) 3; a “smart” insulin meant to switch itself on as glucose rises has worked in animals and has not been given to people
- Insulin as a nasal spray was tested for memory in Alzheimer’s disease, on the idea that the brain’s own insulin signalling fails; a 289-person randomised trial found no cognitive or functional benefit over a year 2
- It is banned in sport at all times 4 and is misused alongside growth hormone to build muscle; the danger is severe hypoglycaemia, and no trial supports that use
Sources
- Petersen & Shulman, Mechanisms of insulin action and insulin resistance, Physiological Reviews 2018
- Craft et al., Intranasal insulin for mild cognitive impairment and Alzheimer disease dementia, JAMA Neurology 2020
- Insulin icodec (Awiqli), FDA application BLA 761326
- World Anti-Doping Agency Prohibited List
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.